Virtu Financial’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-26,266
| Closed | -$120K | – | 2190 |
|
|
2025
Q3 | $120K | Buy |
+26,266
| New | +$116K | 0.01% | 1012 |
|
|
2025
Q1 | – | Sell |
-39,647
| Closed | -$58K | – | 1989 |
|
|
2024
Q4 | $58K | Buy |
+39,647
| New | +$138K | ﹤0.01% | 1137 |
|
|
2024
Q3 | – | Sell |
-4,086
| Closed | -$31K | – | 1853 |
|
|
2024
Q2 | $31K | Buy |
4,086
+2,731
| +202% | +$36.8K | ﹤0.01% | 975 |
|
|
2024
Q1 | $20K | Buy |
+1,355
| New | +$18.2K | ﹤0.01% | 1167 |
|
|
2023
Q3 | – | Sell |
-492
| Closed | -$42K | – | 1856 |
|
|
2023
Q2 | $42K | Buy |
+492
| New | +$34.7K | ﹤0.01% | 1165 |
|
|
2022
Q4 | – | Sell |
-153
| Closed | -$40K | – | 2098 |
|
|
2022
Q3 | $40K | Buy |
+153
| New | +$89.3K | ﹤0.01% | 1249 |
|
|
2022
Q2 | – | Sell |
-46
| Closed | -$42K | – | 2034 |
|
|
2022
Q1 | $42K | Sell |
46
-58
| -56% | -$49.1K | ﹤0.01% | 1175 |
|
|
2021
Q4 | $106K | Buy |
+104
| New | +$149K | 0.01% | 1114 |
|
|
2021
Q2 | – | Sell |
-26
| Closed | -$146K | – | 2039 |
|
|
2021
Q1 | $146K | Buy |
+26
| New | +$164K | 0.01% | 1192 |
|
|
2019
Q1 | – | Hold |
0
| – | -$15K | – | 1802 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 1406 |
|
|
2018
Q3 | – | Hold |
0
| – | -$33K | – | 2132 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 1818 |
|
Other funds holding SONN
Virtu Financial's SONN Position: Q4 2025 in Review
Virtu Financial sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 26,266 shares — an estimated $120K sold.
Virtu Financial first reported a position in SONN in Q1 2021 and held it in 9 quarters. The position peaked at $146K in Q1 2021. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Virtu Financial reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Virtu Financial sold 26,266 Sonnet BioTherapeutics shares in Q4 2025, an estimated $120K.
- Virtu Financial first reported a position in Sonnet BioTherapeutics in Q1 2021 and held it in 9 quarters.
- Virtu Financial's Sonnet BioTherapeutics position peaked at $146K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.